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Circadian secretion of the incretin, glucagon-like peptide-1 (GLP-1), correlates with expression 
of the core clock gene, Bmal1, in the intestinal L-cell. Several SNARE proteins known to be 
circadian in pancreatic α- and β-cells are also necessary for GLP-1 secretion. However, the role 
of the accessory SNARE, Syntaxin binding protein-1 (Stxbp1; also known as Munc18-1) in the 
L-cell is unknown. The aim of this study was to determine whether Stxbp1 is under circadian 
regulation in the L-cell and its role in the control of GLP-1 secretion. Stxbp1 was highly-enriched 
in L-cells, and STXBP1 was expressed in a subpopulation of L-cells in mouse and human intestinal 
sections. Stxbp1 transcripts and protein displayed circadian patterns in mGLUTag L-cells line, while 
chromatin-immunoprecipitation revealed increased interaction between BMAL1 and Stxbp1 
at the peak time-point of the circadian pattern. STXBP1 recruitment to the cytosol and plasma 
membrane within 30 minutes of L-cell stimulation was also observed at this time-point. Loss of 
Stxbp1 in vitro and in vivo led to reduced stimulated GLP-1 secretion at the peak time-point 
of circadian release, and impaired GLP-1 secretion ex vivo. In conclusion, Stxbp1 is a circadian 
regulated exocytotic protein in the intestinal L-cell that is an essential regulatory component of 
GLP-1 secretion. (Endocrinology 161: 1–13, 2020)
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Current frontline therapies for patients with type 2 diabetes include glucagon-like peptide-1 (GLP-1) 
mimetics that not only harness the insulin-stimulating 
and glucagonostatic properties of the endogenous 
hormone, but also lower body weight through induc-
tion of satiety (1). A  potential new class of GLP-1-
based therapies currently being investigated involves 
increasing the endogenous secretion of GLP-1 (2). 
However, full development of such an approach re-
quires identification and further understanding of the 
molecular pathways regulating GLP-1 secretion by the 
intestinal L-cell.
L-cells are scattered throughout the intestinal epithe-
lial layer of the gut, but are predominantly localized to 
the distal ileum and colon (3). GLP-1 secretion from 
these cells is stimulated by nutrient ingestion, as well 
as by a variety of endocrine hormones and adipokines, 
bile acids, and intestinal microbial metabolites (4, 5). 
Recent studies have demonstrated that GLP-1 secretion 
is also modulated by the circadian clock, demonstrating 
peak release at the onset of the dark, active period in 
rodents, and differential release by time of day in hu-
mans (6–10). Circadian secretion of GLP-1 has also 
been demonstrated in both murine and human L-cell 
models in vitro, and both suppression and knockout 
of the circadian clock gene, Bmal1, result in dampened 
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GLP-1 release (6, 8, 11). However, although the actions 
of the various L-cell secretagogues are mediated by dif-
ferent signaling pathways, they must all converge on 
the basolateral side of the enteroendocrine L-cell to 
induce exocytosis of the GLP-1-containing secretory 
granules (12).
Regulated exocytosis involves the core SNARE pro-
teins (syntaxin, SNAP, and VAMP), in addition to a host 
of accessory and regulatory proteins (13, 14). Within 
the intestinal L-cell, previous studies have identified the 
core SNAREs, VAMP2 and syntaxin1a (Stx1a), and 2 
calcium-regulated accessory SNAREs, synaptotagmin-7 
and secretagogin, as essential for GLP-1 secretion (10, 
15–17). Furthermore, the regulatory SNARE protein, 
syntaxin-binding protein-1 (Stxbp1; also known as 
Munc18-1), coimmunoprecipitates with VAMP2, 
Stx1a, and SNAP25 in the murine (m) GLUTag L-cell 
line (15, 18).
Recent studies in pancreatic α- and β-cells have dem-
onstrated the existence of circadian rhythms in VAMP2, 
SNAP25, synaptotagmin-7, and Stxbp1, in association 
with circadian secretion of the associated hormones, 
glucagon and insulin, respectively (19, 20). However, 
although β-cell Stxbp1 knockdown (KD) results in 
impaired exocytosis of insulin (21), nothing is known 
about the regulation of its expression or its role in GLP-1 
secretion by the intestinal L-cell. Notwithstanding, re-
cent microarray and mass spectrometry analyses of the 
mGLUTag intestinal L-cell line have demonstrated that 
Stxbp1 expression is significantly increased at the peak 
time-point of circadian GLP-1 release compared with 
the trough time-point of secretion (10). The goal of 
the present study was, therefore, to determine whether 
Stxbp1 expression is regulated in a circadian fashion in 
the intestinal L-cell and to establish whether this regu-
latory SNARE protein is required for GLP-1 secretion.
Materials and Methods
In vitro studies
mGLUTag (RRID: CVCL_J406) (22) L-cells are a clonal 
line derived from the distal intestine of a male mouse (18), 
which respond to GLP-1 secretagogues and retain an au-
tonomous circadian clock (6, 23–27). mGLUTag L-cells were 
grown in DMEM containing 10% fetal bovine serum (FBS). 
Two days after plating, they were serum-starved for 12 hours 
in 0.5% FBS, synchronized by a 1-hour shock with 20  µM 
forskolin in 10% FBS, and then incubated for up to 48 hours 
in 10% FBS (6, 8, 10, 11).
For STXBP1 localization analyses, mGLUTag L-cells were 
grown on multiwell microscope slides, synchronized as de-
scribed previously, and then stimulated at the 8-hour time-point 
with 50 µM forskolin plus 50 µM 3-isobutyl-1-methylxanthine 
(IBMX; to chemically increase cAMP levels) in 10% FBS or 
vehicle (control), for up to 60 minutes.
Small interfering RNA (siRNA)-mediated reverse-
transfection was used to KD Stxbp1 in mGLUTag L-cells. 
Transfection media with 50 nM siRNA or scrambled RNA 
(scRNA; SMART pool: ON-TARGETplus Stxbp1 siRNA 
or ON-TARGETplus Non-targeting Pool, respectively; 
Lafayette, CO) and 0.75 µL Dharmafect 3 in 10% FBS was 
placed into the wells and the mGLUTag L-cells were then 
passaged directly into the transfection-media and incubated 
for 72 hours. Cells were studied immediately or were then 
serum-starved, synchronized and incubated for 8 hours, as 
described; the respective siRNA and scRNA were included 
in the media during the serum-starvation and 8-hour incu-
bation steps to maintain the KD (data not shown). Cells 
were used for RNA and protein extraction and GLP-1 
secretion assay.
For GLP-1 secretion assay, mGLUTag L-cells were syn-
chronized and incubated for 8 hours in media with 10% FBS, 
as previously described, and then treated with 10-7 M glucose-
dependent insulinotrophic polypeptide (GIP; to physiolo-
gically increase cAMP levels) or media alone (control) for 2 
hours. Each treatment group comprised 8 wells derived from 
2 separate splits, to make n  =  8. Peptides contained in the 
media and cells were collected using a C18 SepPak (Waters 
Associates, Milford, MA), as reported (6, 24–27), and GLP-1 
levels were determined by Total GLP-1 Radioimmunoassay 
(GLP-1T-36HK, Millipore, Etobicoke, ON, Canada). Secretion 
was expressed as the percentage of the media GLP-1 content 
over the total GLP-1 content (media + cells).
In vivo studies
C57BL/6J Stxbp1 floxed (Stxbp1fl/fl) mice were a generous 
gift from Dr. M.  Verhage (Vrije Universiteit, Amsterdam, 
Netherlands (28)) and were crossed with C57BL/6J Gcg-
CreERT2/+;Rosa26-GCamP3fl/fl mice (Gcg-CreERT2/+; Fig. 
S1A and Supplemental Methods at the following URL: 
http://hdl.handle.net/1807/98201 (29)). The heterozygotes 
were backcrossed to Stxbp1fl/fl mice to generate inducible 
Gcg-CreERT2/+; Rosa26-GCamP3fl/fl;Stxbp1fl/fl knockout 
(KO) mice. Mice that were homozygous for the Stxbp1 
floxed gene and positive for Gcg-CreERT2/+ were classified 
as inducible L-cell Stxbp1 KO mice (Table S1 and Fig. S1B 
in File Inventory (29)); expression of the GCamP3 reporter 
was not a consideration for the current study. KO was in-
duced by intraperitoneal injection of tamoxifen (1 mg/d) in 
sunflower oil (vehicle) for 5 days. Control animals included 
Gcg-CreERT2/+;Stxbp1fl/fl mice treated with vehicle, and 
Stxbp1fl/fl and Gcg-CreERT2/+ animals both with and without 
tamoxifen (Fig. S1C in File Inventory (29)). All animals were 
housed under a 12:12 light:dark cycle (lights on at 0600; 
zeitgeber time [ZT] 0) and were fed ad libitum. The study in-
cluded both male- and female-matched, litter- and/or colony-
mates at 7 to 12 weeks of age (except for the study analyzing 
GIP levels, in which mice were 8 to 20 weeks of age). All 
breeding and experimental procedures were approved by the 
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all procedures followed Canadian Council on Animal Care 
guidelines.
An oral glucose tolerance test (OGTT) was performed 7 to 
9 days following treatment with tamoxifen or vehicle (6, 24, 
27). KO and control mice were fasted for 4 hours before the 
OGTT, which was conducted at the established peak GLP-1 
secretory time-point in mice (ZT14) (10), in the dark under 
a red light. A  glucose meter (OneTouch, LifeScan, Burnaby, 
BC, Canada) was used to measure blood glucose levels from 
tail vein blood, before oral gavage of 40% glucose (4  g/kg 
body weight) at t = 0 min, and then at t = 10, 30, 45, 60, 90, 
and 120 minutes (of note, pilot studies indicated that a 5 g/
kg glucose load in this strain of mice resulted in glycemia that 
was above the limit of detection; data not shown). Tail vein 
blood (100 µL) was collected into EDTA at t = 0, 10, and 60 
minutes for measurement of plasma total GLP-1 and insulin 
levels using the Meso Scale Discovery Multi-Spot Assay (Meso 
Scale Diagnostics, Rockville, MD (6)), and glucagon or GIP by 
ELISA (CrystalChem, Elk Grove Village, IL).
One-day following the OGTT, mice were weighed and sac-
rificed, and the small intestine and colon were weighed and the 
lengths taken under contact tension. Two centimeters sections 
were flash-frozen for molecular analysis or fixed in 10% for-
malin for imaging. A segment of ileum was also used to pre-
pare primary cell cultures, as discussed next.
Ex vivo studies
Adult mouse ileal crypt cell cultures were derived from 
approximately 10  cm of ileum, as previously reported (16). 
In brief, isolated crypts were suspended in 10% FBS-DMEM 
(with 2  mM L-glutamine, 100 U/mL penicillin, 0.1  mg/
mL streptomycin, and 0.1% v/v ROCK Inhibitor [Y-27632, 
Sigma-Aldrich]) and crypts from 1 ileum were plated onto a 
24-well plate coated with Corning Matrigel (ThermoFisher 
Scientific) and incubated at 37°C with 5% CO2.
GLP-1 secretion assays were conducted 24-hour after crypt 
plating, as reported (16). Briefly, the cells were washed and 
then treated with 50  µM forskolin/50  µM IBMX or media 
alone (control) for 2 hours. Four wells were tested for each 
treatment group to make n  =  1 per mouse. GLP-1 concen-
trations in the media and cell lysates were measured using a 
GLP-1 (active) ELISA kit (Millipore). Secretion was expressed 
as a percentage of the media GLP-1 content over the total 
GLP-1 content (media + cells).
Analyses
RNA-seq. The methods for fluorescent assisted cell sorting 
of L- and EEC-cells, using either the expression of a yellow 
fluorescent reporter in transgenic GLU-Venus mice or 
NeuroD1-Cre x Rosa26EYFP mice (a generous gift from 
Andrew Leiter) or immunostaining of human tissue isolates 
with fluorescent antibodies, have been previously described 
(30). RNA isolation and sequencing are described elsewhere 
(30, 31) and the data are deposited in the NCBI GEO reposi-
tory (human, GSE114853; mouse, GSE114913). The studies 
were conducted in accordance with the principles of the 
Declaration of Helsinki and good clinical practice. Human 
ethical approvals were given by Cambridge Central and 
South Research Ethics Committees (ref: 09/H0308/24, 16/
EE/0338, 15/EE/0152) and the Inserm ethics committee and 
Agence de la biomédecine (ref: PFS16-004). Animal work was 
regulated under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 and conducted following eth-
ical review by the University of Cambridge Animal Welfare 
and Ethical Review Body.
Chromatin-immunoprecipitation (ChIP). Two canonical 
E-box sequences (CACGTG) were identified at 2016 and 
646  bp upstream of the 5′ transcription start site of the 
Stxbp1 gene. ChIP was conducted using the SimpleChIP 
Enzymatic Chromatin IP Kit with Magnetic Beads #9003 (Cell 
Signalling) according to the manufacturer’s instructions and 
as previously described (10). Briefly, mGLUTag L-cells were 
fixed at 8 and 20 hours after cell synchronization, followed 
by DNA digestion and incubation with Bmal1 antibody (Cell 
Signaling Technology). Protein was precipitated using protein 
G magnetic beads and DNA was eluted and quantified by 
RT-quantitative PCR (RT-qPCR) (Table S2 in File Inventory 
(29)). Signal from each immunoprecipitation was calculated 
as a percent of the total input chromatin using the following 
formula: Signal relative to input=2%×.
RNA isolation and gene expression analysis. Total RNA was 
isolated from cells and tissue using the PARIS (Invitrogen, 
Burlington, ON, Canada) and Qiashredder/RNeasy Plus 
(Qiagen Inc., Toronto, ON, Canada) kits, respectively. RNA 
was then reverse-transcribed and DNAse-treated using 
5X-All-In-One RT MasterMix with AccuRT Genomic DNA 
Removal Kit (Applied Biological Materials Inc., Richmond, 
BC, Canada). Gene expression was quantified using qPCR 
with TaqMan Fast Advanced Master Mix (Table S3 in File 
Inventory (29); ThermoFisher Scientific). Data were analyzed 
using the ΔΔCT method with Histone3a or 18S as the internal 
control for cells and tissues, respectively (32).
Protein isolation and immunoblot. Protein from the 
mGLUTag L-cells was isolated using the PARIS (Invitrogen) 
kit and quantified by Bradford Assay. Samples were run on a 
10% SDS-PAGE gel, transferred to a polyvinylidene fluoride 
membrane and incubated overnight at 4°C with anti-STXBP1 
or anti-BMAL1 and anti-HISTONE H3 (loading control) 
antisera in TBST-T (33–35); molecular weights were deter-
mined with a biotinylated ladder (Table S4 in File Inventory 
(29)). Blots were then incubated with HRP-linked secondary 
antibodies for 1 hr (36, 37), and imaged using Signalfire Elite 
Enhanced Chemiluminescent reagent (New England Biolabs, 
Whitby, ON, Canada).
Immunocytochemistry. After treatment for up to 60 min-
utes with forskolin/IBMX, the plasma membrane of live 
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Agglutinin-Alexa Fluor 488 Conjugate (ThermoFisher 
Scientific) in Hanks’ balanced salt solution at 37°C for 10 
minutes. Cells were then fixed in paraformaldehyde, perme-
abilized with Triton X-100, and blocked with BSA before ap-
plying anti-STXBP1 antibody (BD Bioscience, San Jose, CA 
(33)) for 2 hours at 20°C (Table S4 in File Inventory (29)). 
After washing, cells were incubated with AlexaFluor555-
coupled secondary antibody for 1 hour (ThermoFisher 
Scientific (38)), mounted with Vectashield containing DAPI 
(Vector Laboratories, Burlington, ON, Canada), and imaged 
using a Nikon Swept Field Confocal microscope and NIS-
Elements Imaging software (Nikon Corporation, Melville, 
NY). STXBP1 expression and localization were determined 
by: (1) the ratio of the intensity of STXBP1 expression in ran-
domly selected, defined regions of interest in the cytoplasm 
and nucleus (i.e., cytoplasmic STXBP1 intensity/cytoplasmic 
area) / (nuclear STXBP1 intensity/nuclear area); and (2) 
Pearson’s correlation coefficient for colocalization of STXBP1 
immunostaining with staining by the membrane marker.
Immunofluorescence. Formalin-fixed paraffin-embedded normal 
and L-cell STXBP1 KO mouse ileal and colonic sections 
(UHN Pathology Services, Toronto, ON, Canada) and normal 
human ileal sections (OriGene, Rockville, MD; sample ID 
#PA11B41805, PA00009BED, PA00000353, PA00000426, 
PA15476907, and PA15476916) were costained for STXBP1 
and GLP-1 by antigen-retrieval using Retrievagen A  (BD 
Bioscience), blocking and then incubation with anti-STXBP1 
and anti-GLP-1 antibodies overnight at 4°C (Table S4 in File 
Inventory (29)). AlexaFluor488- and 555-coupled secondary 
antibodies were then applied for 1 hour, followed by imaging 
as described previously (33, 38–40).
Statistical analyses. Data are presented as mean ± SEM. 
The statistical difference between 2 groups was calculated 
by Student t-test, and by 1- or 2-way ANOVA followed 
by a Tukey post hoc test for data with 3 or more groups 
in Microsoft Excel and GraphPad Prism, respectively. The 
24- to 48-hour gene expression data were analyzed using 
JTK_CYCLE for determination of circadian significance and 
period (11).
Results
GLP-1 and Stxbp1 are coexpressed in a sub-
population of primary mouse and human 
intestinal L-cells
RNA-seq analysis of primary L-cells from murine 
and human intestines demonstrated marked enrichment 
of L-cell Stxbp1 and STXBP1 transcript levels, respect-
ively, as compared with non-L-cells throughout the 
small intestine and colon of mice as well as in the small 
intestine of humans (Fig. 1A, B). However, Stxbp1 and 
STXBP1 were not exclusive to the L-cell, demonstrating 
expression in other enteroendocrine cells in humans 
and likely in mice, although the signal observed in 
NeuroD1-EYFP enteroendocrine cells might have arisen 
partially from L-cells included in this population as, in 
a recent single-cell RNA-seq study of colonic endo-
crine cells, Stxbp1 expression was equivalent in L- and 
somatostatin-expressing D- and serotonin-producing 
enterochromaffin-cells (41).
Costaining of mouse ileal tissue for GLP-1 and 
STXBP1 revealed 3 distinct populations of cells in the 
epithelium: cells that expressed only GLP-1 (GLP1+/
STXBP1-), those that coexpressed both GLP-1 and 
STXBP1 (GLP1+/STXBP1+), and a third popula-
tion that expressed STXBP1 only (GLP1-/STXBP1+; 
Fig.  1C, D). In accordance with current literature 
(42), the total number of GLP1+ cells was greater 
in the crypt than the villus (59.4 ± 3.9% for mouse, 
P < 0.01; 57.8 ± 7.8% for human). However, notably, 
many of the GLP1+ L-cells in the mouse ileum did not 
express detectable levels of immunoreactive STXBP1 
(P < 0.001 and P < 0.05 for villus and crypt, respect-
ively), whereas an even smaller percentage of the cells 
were STXBP1+ but GLP1- (P < 0.001 for villus; Fig. 1C, 
D). Costaining of human ileal sections revealed the 
same 3 populations of cells, with similar patterns in 
GLP-1 and/or STXBP1 expression, except that the re-
duction in GLP-1+/STXBP1+ cells in the villus did not 
reach significance (Fig. 1E, F).
Stxbp1 demonstrates a circadian pattern 
of expression in mGLUTag L-cells regulated 
by BMAL1
As we have previously reported higher expression 
of both Stxbp1 transcript and STXBP1 protein levels 
at the peak time-point of GLP-1 secretion as com-
pared with the trough (i.e., 4-8 vs. 16-20 hours after 
synchronization, respectively) (6, 10), synchronized 
mGLUTag L-cells were analyzed over 48 hours for the 
existence of a circadian rhythm. Stxbp1 levels peaked 
at 8 and troughed at 20 hours, demonstrating a sig-
nificant rhythm with a period of 24 hours (P < 0.05; 
Fig. 2A) that dampened over time, as well-established 
to occur for the circadian clock in other cells in vitro 
(43). Consistent with this finding, STXBP1 dem-
onstrated a 4-hour translational delay, peaking at 
12 hours with a 24-hour period (P  <  0.05; Fig.  2B). 
Additionally, the Stxbp1 rhythm was identical to that 
observed for BMAL1 expression, which peaked at 8 
hours and troughed at 20 hours (P < 0.01; Fig. 2C) as 
previously reported (6, 10).
ChIP analysis was conducted to determine whether 
BMAL1 might directly regulate Stxbp1 expression. 
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both 8 and 20 hours after mGLUTag L-cell synchron-
ization (P < 0.001); however, binding was significantly 
greater at 8 hours compared to 20 hours for each E-box 
(P < 0.001; Fig. 2D, E). All further studies were there-
fore conducted at the peak time-point of GLP-1 secre-
tion, 8 hours postsynchronization in mGLUTag L-cells 
and ZT14 (8 pm) in vivo (6, 10).
STXBP1 is translocated to the mGLUTag L-cell 
cytosol and plasma membrane upon stimulation 
of GLP-1 secretion
To determine whether STXBP1 localization is altered 
upon stimulation of GLP-1 secretion, an acute temporal 
analysis was conducted in mGLUTag L-cells 8 hours after 
synchronization. Under basal conditions, similar levels 
Figure 1. GLP-1 and Stxbp1 are coexpressed in a subpopulation of primary mouse and human intestinal L-cells. RNA-seq for Stxbp1 
in isolated murine Gcg-Venus L-cells, or general enteroendocrine cells (EEC), including L-cells (NeuroD1EYFP), and surrounding intestinal epithelial 
cells (A), dominated by nonenteroendocrine enterocytes (negative controls; neg), from mouse (n = 2–3) and (B) from L-cells, other enteroendocrine 
(excluding L-cells) and nonenteroendocrine cells from human (n = 2-11) sections along the intestine as indicated. Statistical analysis by 2-way 
ANOVA for murine (grouped according to tissue and fluorescent positive vs negative for GLU-Venus and NeuroD1EYFP sorts separately) and 1-way-
ANOVA for human tissue. **P < 0.01, ***P < 0.001. (C-F) Immunostaining of (C-D) mouse (n = 4) and (E-F) human (n = 6) ileal sections for GLP-1 
and STXBP1; DAPI (blue) shows the nuclei. (C,E) Representative images and the proportion of cells staining for each marker in the crypt (blue bars) 
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of STXBP1 expression were observed in the cytoplasm 
and nucleus (Fig. 3A, B). However, this pattern changed 
at 30 minutes (but not at 10 or 60 minutes) after stimu-
lation with the known secretagogue, forskolin (16, 23), 
with a 225% increase in immunoreactivity detected in 
the cytoplasm (P < 0.001). STXBP1 immunoreactivity 
was also detected at the cell membrane under basal 
conditions, colocalizing with the membrane marker 
(Pearson correlation coefficient  =  0.48, Fig.  3A, C). 
However, after 30 minutes of stimulation, there was 
again a change in STXBP1 localization, with a 38% in-
crease in expression at the plasma membrane (P < 0.05). 
These subcellular shifts in STXBP1 with stimulation 
suggest recruitment toward the plasma membrane in as-
sociation with increased GLP-1 exocytosis.
KD of Stxbp1 in mGLUTag L-cells impairs GLP-1 
secretion in vitro
Pilot studies in unsynchronized mGLUTag L-cells 
demonstrated 66% and 92% reductions in Stxbp1 and 
STXBP1 levels, respectively, after 72 hours of Stxbp1 
siRNA reverse-transfection (P < 0.05-0.01). Stxbp1 KD 
did not alter the expression of other key SNARE tran-
scripts (Stx1a, Stx1b, Stx2-4, Stxbp2, Stxbp3; Fig. S2 in 
File Inventory (29)).
Stxbp1 KD in synchronized mGLUTag L-cells 
achieved a 49% reduction in Stxbp1 expression at the 
8-hour time-point (P < 0.001; Fig. 4A), at which time a 
2-hour GLP-1 secretion assay was conducted. ScRNA-
transfected, control cells demonstrated a 3.1-fold in-
crease in GLP-1 secretion in response to the known GLP-1 
Figure 2. Stxbp1 demonstrates a circadian pattern of expression in mGLUTag L-cells that is regulated by BMAL1. mGLUTag L-cells were 
synchronized and analyzed for up to 48 hours by (A) RT-quantitative PCR for Stxbp1 and by (B) Western blot for STXBP1 and (C) BMAL1. (D-E) 
mGLUTag L-cells were analyzed by ChIP, at 8 and 20 hours following synchronization, for BMAL1 binding to the E-boxes at (D) -2016 bp and (E) 
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secretagogue, glucose-dependent insulinotrophic  poly-
peptide (GIP (6, 11, 23)), P  <  0.001; Fig.  4B). Basal 
GLP-1 secretion was significantly increased following 
Stxbp1 KD, by 10.9% (P  <  0.01). In contrast, GIP-
stimulated GLP-1 secretion was abolished by the KD, 
and the overall response was reduced by 74.9% as 
compared to GIP-stimulated control cells (P  <  0.01; 
Fig. 4B). This impairment in secretory response was not 
due to altered GLP-1 levels, as both Gcg expression (the 
gene encoding GLP-1) and the total GLP-1 content of 
the cultures did not differ between siRNA- and scRNA-
treated cells (Fig.  4C, D). Collectively, these findings 
demonstrate an essential role for Stxbp1 in peak GLP-1 
secretion by synchronized mGLUTag L-cells.
KO of Stxbp1 in the primary L-cell impairs GLP-1 
secretion in vivo
Inducible Stxbp1 KO mice were developed to deter-
mine the role of Stxbp1 in GLP-1 release by the pri-
mary L-cell (Fig. S1 in File Inventory (29)). RT-qPCR 
Figure 3. STXBP1 is translocated to the mGLUTag L-cell membrane upon stimulation of GLP-1 secretion. Eight hours after synchronization, 
mGLUTag L-cells were treated with 50 µM forskolin (F) plus 50 µM IBMX (I) for up to 60 minutes and then immunostained for STXBP1; Wheat 
Germ Agglutinin was used for the membrane marker. (A) Representative images, (B) STXBP1 cytoplasmic to nuclear intensity ratio (n = 7–9) and (C) 
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of colonic mucosa did not demonstrate any change in 
Stxbp1 expression in the KO mice (Fig. 5A), likely be-
cause of the rarity of L-cells in the intestine (less than 
0.5% of total epithelial cells (44)). The mice also did 
not demonstrate changes in mucosal transcripts for 
Gcg or other SNARE isoforms (Fig.  5A), or in body 
weight or intestinal weights and lengths (Fig. S3 in 
File Inventory (29)). Nonetheless, successful reduction 
of STXBP1 expression in the L-cell was confirmed by 
immunofluorescence, with a 43.8% decrease in the pro-
portion of GLP-1+/STXBP1+ cells in the colon of KO 
mice (Fig. 5B).
In contrast to the findings following Stxbp1 KD in 
the mGLUTag L-cells, 4-hour fasting plasma GLP-1 
concentrations were not altered by L-cell Stxbp1 KO, 
nor were any changes in fasting plasma insulin or blood 
glucose levels detected (Fig. 6A–C). However, whereas 
GLP-1 levels rose significantly at t  =  10 minutes in 
Figure 5. Validation of the L-cell Stxbp1 KO in vivo. (A) Colonic mucosal scrapes from L-cell Stxbp1 KO and control mice were analyzed by 
RT-qPCR for expression of various SNARE proteins as well as Gcg (n = 8–9). (B) Colonic sections from L-cell Stxbp1 KO and control mice were 
analyzed by immunostaining for coexpression of STXBP1 and GLP-1 (n = 4). ***P < 0.001. CON, control; KO, knockout.
Figure 4. Knockdown of Stxbp1 in the mGLUTag L-cell impairs GLP-1 secretion in vitro. mGLUTag cells were treated with siRNA for 
Stxbp1 or scRNA (control), synchronized and then either analyzed at the 8-hour time-point by RT-quantitative PCR for (A) Stxbp1 and (C) Gcg, or 
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control animals in response to the oral glucose load 
(by 368.9%; P < 0.001), the response in L-cell Stxbp1 
KO mice was markedly impaired (by 50.1%; P < 0.01). 
This loss of GLP-1 did not result in any significant 
dampening of insulin secretion or an impairment in 
glucose tolerance during the OGTT. No sex differences 
were observed between males and females for any of the 



































































































































Figure 6. KO of Stxbp1 in the primary L-cell impairs GLP-1 secretion in vivo. (A) Plasma GLP-1, (B) plasma insulin, (C) blood glucose, (D) 
plasma glucagon, (E) plasma GIP levels and comparative delta area-under-the-curve (dAUC) for (F) the GLP-1 and GIP responses, following a 
4 g/kg OGTT administered at ZT14 (8 pm) to L-cell Stxbp1 KO and control mice (n = 9, A-C; n = 3–5, D-E). *P < 0.05. GIP, glucose-dependent 
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Given that the Gcg promoter used to generate the 
Stxbp1 KO is expressed not only in the intestinal L-cell, 
but also the pancreatic α-cell (45, 46) (Supplemental 
Methods in File Inventory (29)), plasma glucagon levels 
were determined in a subset of the mice. However, no 
differences were observed in glucagon concentrations 
between KO and control animals under either basal 
conditions or following the OGTT (Fig.  6D). Plasma 
GIP levels were also determined because increased se-
cretion of this incretin hormone is known to compen-
sate for the constitutive absence of GLP-1 signaling in 
mice (47, 48). Although slightly elevated at both 10 and 
60 minutes, plasma GIP levels did not differ significantly 
between KO and control animals (Fig. 6E). Nonetheless, 
the delta-area under the curve for the overall GLP-1 
response was decreased in the KO mice (by 54%; 
P < 0.05), and this was paralleled by a 23% increase in 
the delta-area under the curve for GIP (Fig 6F).
KO of Stxbp1 in the L-cell impairs GLP-1 
secretion ex vivo
Finally, primary ileal crypt cultures derived from 
Stxbp1 KO mice also demonstrated no differences in 
basal GLP-1 secretion compared with cultures from 
control mice (Fig. 7). However, a 27.5% reduction in 
2-hour forskolin/IBMX-stimulated GLP-1 secretion 
was observed in the Stxbp1 KO cultures as compared to 
those derived from control animals (P < 0.05), despite 
similar GLP-1 content.
Discussion
The push to develop new classes of GLP-1-based ther-
apies has led to identification of novel secretagogues 
regulating GLP-1 release from the L-cell (2). As an al-
ternative approach (49), the pathway governing exo-
cytosis of the GLP-1-containing secretory granules 
may serve as a potential therapeutic target. Studies fo-
cused on the role of the SNARE proteins in GLP-1 se-
cretion are currently in early stages, with only the core 
proteins, VAMP2 and syntaxin1a, and the accessory 
proteins, synaptotagmin-7 and secretagogin, being 
identified to date as regulators of GLP-1 secretion (10, 
15–17). The results of the present study contribute to 
this growing body of work, by identifying the regula-
tory SNARE protein, Stxbp1, as a novel regulator of 
GLP-1 secretion. Using in vitro, in vivo, and ex vivo 
models, this study demonstrated that the loss of Stxbp1 
in L-cells leads to a significant reduction in stimulated 
GLP-1 secretion. Furthermore, a relationship between 
the expression of Stxbp1 and the clock gene, Bmal1, 
identified Stxbp1, along with secretagogin (10), as a 
putative determinant of the circadian pattern of GLP-1 
secretion.
Although L-cell Stxbp1 deficiency impaired stimu-
lated GLP-1 secretion in all models tested, the decrease 
in the GLP-1 response to an OGTT, unexpectedly, 
did not result in any significant alterations in either 
plasma insulin levels or glycemia. These findings stand 
in contrast to the reduced insulinemia and impaired 
glucose tolerance observed with the loss of GLP-1 se-
cretion in the syntaxin1a KO mouse (16). However, the 
syntaxin1a KO mouse was generated using the Villin-
CreERT2/+ construct, which targets all intestinal epithe-
lial cells, resulting in impaired secretion of GIP which, 
presumably, contributed to the phenotype. Conversely, 
increased GIP secretion compensates for chronic loss of 
GLP-1 action, accompanied by enhanced β-cell sensi-
tivity to the insulinotrophic actions of GIP (47, 48, 50). 
Although we did not determine GIP receptor signaling 
in the present acute study, the results are consistent with 
an adaptive role for GIP in limiting hyperglycemia in 
the L-cell Stxbp1 KO mice. Importantly, given that the 
expression of the Gcg-CreERT2/+ construct is not con-













































Figure 7. KO of Stxbp1 in the primary L-cell impairs GLP-1 
secretion ex vivo. GLP-1 secretion assay in primary adult mouse 
ileal crypt cultures from L-cell Stxbp1 KO and control mice. Cells 
were treated for 2 hours with 50 µM forskolin (F) plus 50 µM IBMX 
(I) or vehicle alone (control). (A) Percent GLP-1 secretion and (B) total 
cell content of GLP-1. (n = 6–7). *P < 0.05, ***P < 0.001. CON, 
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pancreatic α-cell (45, 46), as well as the reported ex-
pression of Stxbp1 in the α-cell (20, 51, 52), use of this 
construct to generate the L-cell Stxbp1 KO mice was 
plausibly predicted to affect the secretion of glucagon. 
However, although plasma glucagon levels were sup-
pressed normally during the OGTT, no change in fasting 
glucagon levels was observed, suggesting that Stxbp1, 
which is expressed at lower levels in α compared with 
β and δ cells (53) plays a minor role and/or is redun-
dant for glucagon secretion. Finally, although possible 
effects of Stxbp1 KO in Gcg-expressing neurons of the 
CNS could not be accounted for in the present study, no 
changes in body weight were noted in the experimental 
animals.
Importantly, STXBP1 expression was detected in 
some, but not all ileal L-cells in both mice and humans, 
consistent with recent studies demonstrating that L-cells 
are not identical either along the length of the intestinal 
tract or across the crypt-villus axis (41, 42, 54). Indeed, 
our recent study has demonstrated that differential re-
ceptor expression by subpopulations of colonic L-cells 
results in profound differences in sensitivities to known 
secretagogues (41). Hence, the marked effect of Stxbp1 
KO on the L-cell response to an OGTT in vivo and to 
forskolin ex vivo suggest a significant role for this regu-
latory SNARE protein in GLP-1 secretion by a unique 
population of intestinal L-cells. These findings further 
raise the intriguing possibility that Stxbp1 may serve as 
a marker for secretagogue-specific L-cell responses.
STXBP1 was found to translocate within the 
mGLUTag L-cells upon stimulation with forskolin, to-
ward the cytoplasm and the cell membrane. Nuclear 
expression of STXBP1 has been reported in both 
neurons and PC12 cells, although its function therein 
remains unknown (55). However, in many neuro/endo-
crine cell types, STXBP1 binds to Syntaxin1 during its 
translocation through the cytosol to the plasma mem-
brane, maintaining Syntaxin1 in its “closed” conform-
ation to prevent premature SNARE fusion. However, at 
the cell membrane, STXBP1 primes core SNARE fusion 
by inducing the “open” conformation of syntaxin1 (21, 
56, 57). As syntaxin1a is expressed by intestinal L-cells 
(16), and STXBP1 interacts with Syntaxin1a in the 
mGLUTag L-cell line (15), these results are consistent 
with a role for Stxbp1 as a regulator of Syntaxin1a 
function in the L-cell.
In conclusion, the results of this study demon-
strate a key role for the regulatory SNARE protein, 
STXBP1, in GLP-1 secretion from the intestinal L-cell. 
Consistent with data implicating Stxbp1 in the cir-
cadian secretion of glucagon and insulin (20), the 
present study identifies the Stxbp1 promoter as a 
time-dependent target of BMAL1, and demonstrates 
the existence of a circadian rhythm in Stxbp1 tran-
script and protein expression in L-cells. When taken 
with reports that Stxbp1 expression is reduced in is-
lets from patients with type 2 diabetes, as well as from 
the Goto-Kakizaki rat model of type 2 diabetes (52, 
58, 59), these findings suggest Stxbp1 as a potential 
target to enhance not only insulin secretion, but also 
GLP-1 release.
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